Company Encyclopedia
View More
name
Tofflon
300171.SZ
Tofflon Science and Technology Group Co., Ltd. engage in the research, development, production, sales, and services of pharmaceutical equipment in China and internationally. It operates through four segments: Biotechnology, Preparation Equipment, Engineering, and Food Engineering. The company offers technological research, such as cell technology, complex preparation, injection, and OSD laboratory; instruments, including cell therapy and nucleic acid drugs instruments, and table reactor; cryopreservation system for seeds and biological samples, and freeze-thaw system of biological stock solution; and single use technology, such as bioreactor, liquid distribution system, sterile bag, process chromatography, membrane filtration system, and others.
890.25 B
300171.SZMarket value -Rank by Market Cap -/-

Financial Score

06/12/2025 Update
C
Health Care EquipmentIndustry
Industry Ranking33/63
Industry medianC
Industry averageC
Score Analysis
Peer Comparison
  • Criteria
    Rating
  • Profit ScoreC
    • ROE2.21%C
    • Profit Margin3.31%C
    • Gross Margin40.84%B
  • Growth ScoreC
    • Revenue YoY8.70%B
    • Net Profit YoY1.97%C
    • Total Assets YoY1.66%C
    • Net Assets YoY0.43%C
  • Cash ScoreB
    • Cash Flow Margin3021.21%A
    • OCF YoY8.70%B
  • Operating ScoreC
    • Turnover0.4C
  • Debt ScoreB
    • Gearing Ratio39.19%B

Valuation analysis

portai
P/E
1Y
3Y
5Y
10Y
P/E
-
Industry Ranking
-/-
  • P/E
  • Price
  • High
  • Median
  • Low
P/B
1Y
3Y
5Y
10Y
P/B
-
Industry Ranking
-/-
  • P/B
  • Price
  • High
  • Median
  • Low
P/S
1Y
3Y
5Y
10Y
P/S
-
Industry Ranking
-/-
  • P/S
  • Price
  • High
  • Median
  • Low
Dividend Yield
1Y
3Y
5Y
10Y
Dividend Yield
-
Industry Ranking
-/-
  • Dividend Yield
  • Price
  • High
  • Median
  • Low

Institutional View & Shareholder

Analyst Ratings

Rating
Percentage
    • Price
      --
    • Highest
      --
    • Lowest
      --
    News
    View More

    Tofflon released its performance for the first three quarters, with a net profit attributable to the parent company of 132 million yuan, a decrease of 13.86%

    According to the Zhitong Finance APP, Tofflon released its third-quarter report for 2025. The company's operating revenue for the first three quarters was 3.704 billion yuan, a year-on-year increase of 6.14%. The net profit attributable to shareholders of the listed company was 132 million yuan, a year-on-year decrease of 13.86%. The net profit attributable to shareholders of the listed company after deducting non-recurring gains and losses was 105 million yuan, a year-on-year decrease of 20.15%. The basic earnings per share were 0.1729 yuan

    Zhitong·
    SZ
    300171
    +1.49%
    Zhitong·
    SZ
    300171
    +1.49%

    Tofflon and others established a biotechnology company with a registered capital of 100 million yuan

    According to the Qichacha APP, recently, Yantai Bosai Biotechnology Co., Ltd. was established with a registered capital of 100 million yuan. Its business scope includes drug production, drug wholesale, drug retail, and drug contract manufacturing, among others. Qichacha's equity penetration shows that the company is jointly held by Tofflon and others

    Zhitong·
    SZ
    300171
    +1.49%
    Zhitong·
    SZ
    300171
    +1.49%

    Tofflon released its performance for the first half of the year, with a net profit attributable to the parent company of 45.9195 million yuan, a decrease of 59.71%

    Tofflon released its 2025 semi-annual report, with operating revenue of 2.429 billion yuan, a year-on-year increase of 6.01%. The net profit attributable to shareholders was 45.9195 million yuan, a year-on-year decrease of 59.71%; the net profit after deducting non-recurring gains and losses was 25.4752 million yuan, a year-on-year decrease of 74.30%. The basic earnings per share were 0.0604 yuan

    Zhitong·
    SZ
    300171
    +1.49%
    Zhitong·
    SZ
    300171
    +1.49%

    Tofflon and THDB signed a strategic cooperation agreement

    According to Tofflon, recently, Tofflon and THDB officially signed a strategic cooperation agreement. The two parties will carry out in-depth cooperation in multiple dimensions such as product research and development, equipment innovation, process optimization, and commercial collaboration, further promoting technological advancement and industrial development in the field of diabetes treatment

    Zhitong·
    SH
    600867
    +0.57%
    SZ
    300171
    +1.49%
    Zhitong·
    SH
    600867
    +0.57%
    SZ
    300171
    +1.49%

    Tofflon: 2025-2027 Shareholder Dividend Return Plan

    Tofflon released its shareholder dividend return plan for 2025 to 2027, emphasizing that profit distribution should focus on reasonable returns for investors, maintain continuity and stability of policies, while also considering the company's sustainable development. The company plans to distribute dividends in cash, stock, or a combination of both, prioritizing cash dividends, and ensuring that the profits distributed in cash over the past three years are no less than 30% of the average distributable profits per year

    Zhitong·
    SZ
    300171
    +1.49%
    Zhitong·
    SZ
    300171
    +1.49%
    © 2025 Longbridge｜Disclaimer